-
Capital, M&A & Industry Strategy4 weeks agoShionogi pays $2B to acquire a rare disease startup
The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.
-
Capital, M&A & Industry Strategy4 weeks agoOptogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the...
-
Capital, M&A & Industry Strategy4 weeks agoThe biggest biotech funding rounds in September 2026
The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August 2026. The post The biggest biotech funding rounds in...
-
Capital, M&A & Industry Strategy4 weeks agoT Cell Receptor Sequencing Reveals Immune Fingerprints in Children with Mycoplasma Pneumonia
Mycoplasma pneumoniae has long been recognized as one of the most common bacterial causes of community-acquired pneumonia in children, yet the way a child’s immune system...
-
Capital, M&A & Industry Strategy4 weeks agoHatteras banks on portfolio with upsized Opportunity Fund
BIOCENTURY | FINANCEHATTERAS BANKS ON PORTFOLIO WITH UPSIZED OPPORTUNITY FUNDFirm sets $100M target for vehicle designed for further investment in private portfolio companies, even amid improved...
-
Capital, M&A & Industry Strategy4 weeks agoTrio of biotechs draw nine-figure fundings: Public Equity Report
BIOCENTURY | FINANCETRIO OF BIOTECHS DRAW NINE-FIGURE FUNDINGS: PUBLIC EQUITY REPORTImmix, Sagimet, and Pyxis all receive funding; plus AstraZeneca/Summit
-
Capital, M&A & Industry Strategy4 weeks agoSpace pharma Varda raises $251m, and other financings
Varda has closed a $251m round to fuel its mission to make medicines in orbit, with TriGemX, Breye, AnaCardio, and ai3Bio also raising new funds.
-
Capital, M&A & Industry Strategy4 weeks agoHidden in plain sight: Canaan’s Grant on company building in white spaces
BIOCENTURY | FINANCEHIDDEN IN PLAIN SIGHT: CANAAN’S GRANT ON COMPANY BUILDING IN WHITE SPACESJulie Grant joins The BioCentury Show to discuss company building toward M&A, what...
-
Capital, M&A & Industry Strategy4 weeks agoKallyope becomes TriGemX, raises $94M for migraine therapy: Venture Report
BIOCENTURY | FINANCEKALLYOPE BECOMES TRIGEMX, RAISES $94M FOR MIGRAINE THERAPY: VENTURE REPORTPlus: At least four rounds for European biotechs; Link Cell’s series A extension; and more
-
Capital, M&A & Industry Strategy4 weeks agoEyeing post-Dupixent years, Regeneron, Sanofi expand immunology collaboration
BIOCENTURY | DEALSEYEING POST-DUPIXENT YEARS, REGENERON, SANOFI EXPAND IMMUNOLOGY COLLABORATIONThe longtime partners bring four more products into their shared portfolio, including a clinical, long-acting IL-13 inhibitor...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
